Boswellia serrata: An overall assessment of in vitro, preclinical, pharmacokinetic and clinical data

Clinical Pharmacokinetics

Volumn 50, Issue 6, 2011, Pages 349-369

  Abdel Tawab, Mona ^a   Werz, Oliver ^b   Schubert Zsilavecz, Manfred ^a,c  

^a ABDA Bundesvereinigung Deutscher Apothekerverbande   (Germany)

^b Pharmaceutical Institute   (Germany)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

Alternative medicine; Anti inflammatories; Antirheumatics; Asthma; Boswellin; Brain oedema; Inflammatory bowel diseases; Osteoarthritis; Rheumatoid arthritis

Indexed keywords

11 KETO BETA BOSWELLIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ACETYL 11 OXO BETA BOSWELLIC ACID; ACETYL ALPHA BOSWELLIC ACID; ACETYL BETA BOSWELLIC ACID; ALPHA BOSWELLIC ACID; ANTIINFLAMMATORY AGENT; ARACHIDONATE 5 LIPOXYGENASE; BETA BOSWELLIC ACID; BOSWELLIA CARTERII EXTRACT; BOSWELLIA SERRATA EXTRACT; BOSWELLIC ACID; CATHEPSIN G; CROMOGLYCATE DISODIUM; DEXAMETHASONE; HISTAMINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; LEUKOCYTE ELASTASE; LEUKOTRIENE; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT; PLANT EXTRACT; PREDNISOLONE; PROSTAGLANDIN E SYNTHASE; ROFECOXIB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALDECOXIB;

ABDOMINAL PAIN; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ASTHMA; BOSWELLIA SERRATA; BRAIN EDEMA; COLITIS; COLLAGENOUS COLITIS; CROHN DISEASE; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG TOLERABILITY; EDEMA; ENTERITIS; GOUT; GRANULOMA; HUMAN; ILEITIS; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MEDICINAL PLANT; NAUSEA; NONHUMAN; OSTEOARTHRITIS; PAW EDEMA; PLASMA CONCENTRATION-TIME CURVE; PLEURISY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; ULCERATIVE COLITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BOSWELLIA; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; INFLAMMATION; MEDICINE, AYURVEDIC; PLANT EXTRACTS;

EID: 79955827648     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11586800-000000000-00000     Document Type: Review

References (111)

1. Jones R, Rubin G, Berenbaum F, et al. Gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Med 2008; 121: 464-74 (Pubitemid 351694347)
2. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998; 105: 31S-8S (Pubitemid 28378015)
3. Delco F, Michetti P, Beglinger C, et al. Health care resource utilization and costs of NSAID-induced gastrointestinal toxicity: a population based study in Switzerland. Digestion 2004; 69: 10-9 (Pubitemid 38332920)
4. Silverstein F, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS Study: a randomized controlled trial. JAMA 2000; 284: 1247-55
5. Farooq M, Haq I, Qureshi AS. Cardiovascular risks of COX inhibition: current perspectives. Expert Opin Pharmacother 2008; 9: 1311-9 (Pubitemid 351877515)
6. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case control study. Lancet 2005; 365: 475-81 (Pubitemid 40215729)
7. Abdel-Tawab M, Zettl H, Schubert-Zsilavecz M. Nonsteroidal anti-in-flammatory drugs: a critical review on current concepts applied to reduce gastrointestinal toxicity. Curr Med Chem 2009; 16 (16): 2042-63
8. Poeckel D, Werz O. Boswellic acids: biological actions and molecular targets. Curr Med Chem 2006; 13: 3359-69 (Pubitemid 44873750)
9. Winking M, Sarikaya S, Rahmanian A, et al. Boswellic acids inhibit glioma growth: a new treatment option? J Neurooncol 2000; 46 (2): 97-103 (Pubitemid 30352616)
10. Basch E, Boon H, Davies-Heerema T, et al. Boswellia: an evidence-based systematic review by the natural standard research collaboration. J Herb Pharmacother 2004; 4 (3): 63-83 (Pubitemid 40674232)
11. Safayhi H, Mack T, Sabieraj J, et al. Boswellic acids: novel, specific nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther 1992; 261: 1143-6
12. Siemoneit U, Pergola C, Jazzar B, et al. On the interference of boswellic acids with 5-lipoxygenase: mechanistic studies in vitro and pharmacological relevance. Eur J Pharmacol 2009; 606 (1-3): 246-54
13. Buechele B, Simmet T. Analysis of 12 different petnacyclic triterpneic acids from frankincense in human plasma by high performance liquid chroma-tography and photdiode array detection. J Chromatogr B 2003; 795: 355-62 (Pubitemid 37186805)
14. Kreck C, Saller R. Indischer Weihrauch und seine Zubereitungen einschlieXlich H15 als traditionelles und modernes Therapeutikum. Internist Prax 1998; 38: 857-72
15. Ennet D, Poetsch F, Groditsch D. Indischer Weihrauch. Dtsch Apoth Ztg 2000; 140: 105-13 (Pubitemid 30236105)
16. Gupta I, Parihar A, Malhotra P, et al. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res 1997; 2 (1): 37-43
17. Krieglstein CF, Anthoni C, Rijcken EJM, et al. Acetyl-11-keto-b-boswellic acid, a constituent of herbal medicine from Boswellia serrata resin, attenuates experimental ileitis. Int J Colorectal Dis 2001; 16: 88-95 (Pubitemid 32318342)
18. Sterk V, Buechele B, Simmet T. Effect of food intake on the bioavailability of boswellic acids from herbal preparation in healthy volunteers. Planta Med 2004; 70: 1155-60 (Pubitemid 40101096)
19. Gupta I, Gupta V, Parihar A, et al. Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study. Eur J Med Res 1998; 3 (11): 511-4
20. Ganzera M, Khan IA. A reversed high performance liquid chromatography method for the analysis of boswellic acids in Boswellia serrata. Planta Med 2001; 67: 778-80 (Pubitemid 33044496)
21. Tawab MA, Kaunzinger A, Bahr U,et al. Developmentof a high-performance liquid chromatographic method for the determination of 11-keto-beta-boswellic acid in human plasma. J Chromatogr B Biomed Sci 2001; 761 (2): 221-7 (Pubitemid 32817112)
22. Sharma S, Thawani V, Hingorani L, et al. Pharmacokinetic study of 11-keto-b-boswellic acid. Phytomedicine 2004; 11: 255-60
23. Tausch L, Henkel A, Siemoneit U, et al. Identification of human cathepsin G as a functional target of boswellic acids from the anti-inflammatory remedy frankincense. J Immunol 2009; 183: 3433-42
24. Ammon HPT. Boswellic acids in chronic inflammatory diseases. Planta Med 2006; 72 (12): 1100-16 (Pubitemid 44638909)
25. Kruger P, Daneshfar R, Eckert GP, et al. Metabolism of boswellic acids in vitro and in vivo. Drug Metab Dispos 2008; 36 (6): 1135-42 (Pubitemid 351717472)
26. Reising K, Meins J, Bastian B, et al. Determination of boswellic acids in brain and plasma by high-performance liquid chromatography/tandem mass spectrometry. Anal Chem 2005; 77 (20): 6640-5 (Pubitemid 41504448)
27. Kruger P, Kanzer J, Hummel J, et al. Permeation of Boswellia extract in the Caco-2 model and possible interactions of its constituents KBA and AKBA with OATP1B3 and MRP2. Eur J Pharm Sci 2009; 36 (2-3): 275-84
28. Gerhardt H, Seifert F,Buvari P, et al. Therapie des aktiven Morbus Crohn mit Boswellia serrata Extrakt H15. Z Gastroenterol 2001;39: 11-17 (Pubitemid 32125556)
29. Gupta I, Parihar A, MalhotraP,et al. Effectsofgum resin ofBoswellia serrata on patients with chronic colitis. Planta Med 2001; 67 (5): 391-5 (Pubitemid 32652571)
30. Madisch A, Miehlke S, Eichele O, et al. Boswellia serrata extract for the treatment of collagenous colitis: a double-blind, randomized, placebo-controlled, multicenter trial. Int J Colorectal Dis 2007; 22: 1445-51 (Pubitemid 47543333)
31. Anthoni C, Laukoetter MG, Rijcken E, et al. Mechanisms underlying the anti-inflammatory actions of boswellic acid derivatives in experimental colitis. Am J Physiol Gastrointest Liver Physiol 2006; 290: G1131-7 (Pubitemid 43788294)
32. Kiela PR, Midura AJ, Kuscuoglu N, et al. Effects of Boswellia serrata in mouse models of chemically induced colitis. Am J Physiol Gastrointest Liver Physiol 2005; 288: G798-808 (Pubitemid 40388192)
33. Yamada T, Deitch E, Specian RD, et al. Mechanisms of acute and chronic intestinal inflammation induced by indomethacin. Inflammation 1993; 17: 641-62 (Pubitemid 23359088)
34. Syrovets T, Buchele B, Krauss C, et al. Acetyl-boswellic acids inhibit lipo-polysaccharide-mediated TNF-a induction in monocytes by direct interaction with IkB kinases. J Immunol 2005; 174: 498-506 (Pubitemid 40007440)
35. Roy S, Khanna S, Shah H, et al. Human genome screen to identify the genetic basis of the anti-inflammatory effects of Boswellia in microvascula en-dothelial cells. DNA Cell Biol 2005; 24: 244-55 (Pubitemid 40490263)
36. h2 cytokines in vitro. Clin Diagn Lab Immunol 2005; 12: 575-80 (Pubitemid 41184716)
37. Moussaieff A, Shein NA, Tsenter J, et al. Incensole acetate: a novel neuro-protective agent isolated from Boswellia carterii. J Cereb Blood Flow Metab 2008; 28: 1341-52 (Pubitemid 351896651)
38. Khajuria A, Gupta A, Suden P, et al. Imunomodulatory activity of biopo-lymeric fraction BOS 2000 from Boswellia serrata. Phytother Res 2008; 22 (3): 340-8 (Pubitemid 351397436)
39. h2 immune responses in mice immunized with HbsAg. Vaccine 2007; 25 (23): 4586-94 (Pubitemid 46745315)
40. Harizi H, Corcuff J-B, Gualde N.Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology. Trends Mol Med 2008; 14 (10): 461-9
41. Ammon HP, Mack T, Singh GB, et al. Inhibition of leukotriene B4 formation in rat peritoneal neutrophils by an ethanolic extract of the gum resin exudate of Boswellia serrata. Planta Med 1991; 57: 203-7
42. Sailer ER, Schweizer S, Boden SE, et al. Acetyl-11-keto-beta-boswelic acid (AKBA): structure requirements for binding and 5-lipoxygenase inhibitory activity. Brit J Pharmacol 1996; 117: 615-8
43. Safayhi H, Sailer ER, Ammon HP. Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-beta boswellic acid. Mol Pharmacol 1995; 47 (6): 1212-6
44. Werz O, Schneider N, Brungs M, et al. A test system for leukotriene synthesis inhibitors based on the in-vitro differentiation of the human leukemic cell lines HL-60 and Mono Mac 6. Naunyn Schmied Arch Pharmacol 1997; 356 (4): 441-5 (Pubitemid 27402082)
45. Werz O, Szellas D, Henseler M, et al. Nonredox 5-lipoxygenase inhibitors require glutathione peroxidase for efficient inhibition of 5-lipoxygenase activity. Mol Pharmacol 1998; 54: 445-50
46. Werz O, Steinhilber D. Therapeutic options for 5-lipoxygenase inhibitors. Pharmacol Ther 2006; 112 (3): 701-8
47. 2+) mobilization. Biochem Biophy Res Commun 2002; 290: 185-90 (Pubitemid 34694481)
48. 2+ mobilisation and MAPK activation of lipid metabolism and peroxide formation in human leucocytes. Br J Pharmacol 2004; 141: 223-32 (Pubitemid 38250892)
49. Safayhi H, Boden SE, Schweizer S, et al. Concentration-dependent po-tentiating and inhibitory effects of Boswellia extracts on 5-lipoxygenase product formation in stimulated PMNL. Planta Med 2000; 66: 110-3 (Pubitemid 30164349)
50. 2+ and differentially interact with platelet-type 12-lipoxygenase. Mol Pharmacol 2006; 70: 1071-8 (Pubitemid 44268464)
51. Boden SE, Schweizer S, Bertsche T, et al. Stimulation of leukotriene synthesis in intact polymorphnuclear cells by the 5-lipoxygenase 3-oxotirucallic acid. Mol Pharmacol 2001; 60: 267-73 (Pubitemid 32678291)
52. Kim JH, Tagari P, Griffiths AM, et al. Levels of peptidoleukotrienes E4 are elevated in active Crohn's disease.J Pediatr Gastroenterol Nutr 1995; 20: 403-7
53. Ikehata A, Hiwatashi N, Kinouchi Y, et al. Altered leukotriene B4 metabo-lism in colonic mucosa with inflammatory bowel disease. Scand J Gastro-enterol 1995; 30: 44-9
54. Murthy S, Murthy NS, Coppola D, et al. The efficacy of BAY y 1015 in dextran sulphate model of mouse colitis. Inflamm Res 1997; 46: 224-33 (Pubitemid 27313734)
55. Zingarelli B, Squadrito F, Graziani P, et al. Effects of zileuton, a new 5-lipoxygenase inhibitor, in experimentally induced colitis in rats. Agents Actions 1993; 39: 150-6 (Pubitemid 23349824)
56. Laursen LS, Naesdal J, Bukhave K, et al. Selective 5-lipoxygenase inhibition in ulcerative colitis. Lancet 1990; 335: 683-5 (Pubitemid 20089307)
57. Hillingso J, Kjeldsen J, Laursen LS, et al. Blockade of leukotriene production by a single oral dose of MK-0591 in active ulcerative colitis. Clin Pharmacol Ther 1995; 57: 335-41
58. Zaher H, Khan AA, Palandra J, et al. Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalzine absorption and elimination in mouse. Mol Pharm 2006; 3 (1): 55-61 (Pubitemid 43331751)
59. Steinhilber D. 5-Lipoxygenase: a target for antiinflammatory drugs revisited. Curr Med Chem 1999; 6: 71-85 (Pubitemid 29068270)
60. Christman JW, Lancaster LH, Blackwell TS. Nuclear factor NFkB: a pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intensive Care Med 1998; 24: 1131-8 (Pubitemid 28542926)
61. Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor kB in in-flammatory bowel disease. Gut 1998; 42: 477-84 (Pubitemid 28186562)
62. Gan H-T, Chen Y-Q, Ouyang Q. Sulfasalzine inhibits activation of nuclear factor-kB in patients with ulcerative colitis. J Gastroenterol Hepat 2005; 20: 1016-24 (Pubitemid 40961223)
63. Rijcken E, KriegeIstein CF, Anthoni C, et al. ICAM-1 and VCAM-1 anti-sense oligonucleotides attenuate in vivo leucocyte adherence and inflammation in rat inflammatory bowel disease. Gut 2002; 51: 529-35
64. Hammato N, Meamura K, Hirate M, et al. Inhibition of dextran sulphate sodium (DSS)-induced colitis in mice by intracolonically administered antibodies against adhesion molecules (endothelial leucocyte adhesion molecule-1 (ELAM-1) or intercellular adhesion molecule-1 (ICAM-1)). Clin Exp Immunol 1999; 117: 462-8
65. van Deventer SJ, Tami JA, Wedel MK. A randomised controlled double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut 2004; 53: 1646-51 (Pubitemid 39434109)
66. Ramakers JD, Mensink RP, Schaart G, et al. Arachidnoic acid but not eicosapentaenoic acid (EPA) and oleic acid activates NF-kB and elevates ICAM-1 expression in Caco-2 cells. Lipids 2007; 42: 687-98 (Pubitemid 47328753)
67. Saklatavala J. Glucocorticoids: do we know how they work? Arthritis Res 2002; 4: 146-50
68. Dabek M, Ferrier L, Roka R, et al. Luminal cathepsin G and protease-acti-vated receptor 4: a duet involved in alterations of the colonic epithelial barrier in ulcerative colitis. Am J Pathol 2009; 175 (1): 207-14
69. Kuwana T, Saot Y, Saka M, et al. Anti-cathepsin G antibodies in the sera of patients with ulcerative colitis. J Gastroenterol 2000; 35 (9): 682-9
70. Ooi CJ, Lim BL, Cheong WK, et al. Antineutrophil cytoplasmic anti-bodies (ANCAs) in patients with inflammatory bowel disease show no correlation with proteinase 3, lactoferrin, myeloperoxidase, elastase, cathep-sin G and lysozyme: a Singapore study. Ann Acad Med Singapore 2000; 29 (6): 704-7 (Pubitemid 33710665)
71. Sander O, Herborn G, Rau R. Is H15 (resin extract of Boswellia serrata, "incense") a useful supplement to established drug therapy of chronic polyarthritis? Results of a double-blind pilot study. Z Rheumatol 1998; 57 (1): 11-6
72. Kimmatkar N, Thawani V, Hingorani L, et al. Efficacy and tolerability of Boswellia serrata extract in the treatment of osteoarthritis of knee: a randomized double blind placebo controlled trial. Phytomedicine 2003; 10: 3-7 (Pubitemid 36262200)
73. Sontakke S, Thawani V, Pimpalkhute P, et al. Open, randomized, controlled clinical trial of Boswellia serrata extract as compared to valdecoxib in osteo-arthritis of knee. Indian J Pharmacol 2007; 39: 27-9 (Pubitemid 46381930)
74. Sengupta K, Alluri KV, Satish AR, et al. A double-blind, randomized, placebo-controlled study of the efficacy and safety of 5-Loxin® for treatment of osteoarthritis of the knee. Arthritis Res Ther 2008; 10 (4): R85
75. Etzel R. Special extract of Boswellia serrata (H15) in the treatment of rheu- matoid arthritis. Phytomed 1996; 3: 91-4 (Pubitemid 126491960)
76. Chopra A, Lavin P, Patwardhan B, et al. Randomized double blind trial of an ayurvedic plant derived formulation for the treatment of rheumatoid arthritis. J Rheumatol 2000; 27 (6): 1365-72 (Pubitemid 30354029)
77. Kulkarni RR, Patki PS, Jog VP, et al. Efficacy of an ayurvedic formulation in rheumatoid arthritis: a double-blind, placebo-controlled, cross-over study. Indian J Pharm 1992; 24: 98-101
78. Singh GB, Singh S, Bani S. Anti-inflammatory actions of boswellic acids. Phytomed 1996; 3 (1): 81-5 (Pubitemid 126491958)
79. Singh GB, Atal CK. Pharmacology of an extract of salai guggal ex-Boswellia serrata, a new non-steroidal anti-inflammatory agent. Agents Actions 1986; 18: 407-12 (Pubitemid 16040728)
80. Fan AY, Lao L, Zhang RX, et al. Effects of an acetone extract of Boswellia carterii Birdw. (Burseraceae) gum resin on rats with persistent inflammation. J Altern Complement Med 2005; 11: 323-31 (Pubitemid 40647169)
81. Fan AY, Lao L, Zhang RX, et al. Effects of an acetone extract of Boswellia carterii Birdw. (Burseraceae) gum resin on adjuvant-induced arthritis in Lewis rats. J Ethnopharmacol 2005; 101 (1-3): 104-9 (Pubitemid 41265608)
82. Gupta OO, Sharma N, Chand D. A sensitive and relevant model for evalu- ating anti-inflammatory activity-papaya latex-induced rat paw inflammation. J Pharmacol Toxicol Meth 1992; 28 (1): 15-9
83. Gupta OO, Sharma N, Chand D. Application of papaya latex-induced rat paw inflammation: model for evaluation of slowly acting antiarthritic drugs. J Pharmacol Toxicol Meth 1994; 31 (2): 95-8 (Pubitemid 24161763)
84. Banno N, Akihisa T, Yasukawa K, et al. Anti-inflammatory activities of the triterpene acids from the resin of Boswellia carteri. J Ethnopharmacol 2006; 107 (2): 249-53 (Pubitemid 44247435)
85. Sharma ML, Khajuria A, Kaul A, et al. Effect of salai guggal ex-Boswellia serrata on cellular and hunoral immune responses and leukocate migration. Agents Action 1988; 24: 161-4
86. Sharma ML, Bani S, Singh GB. Anti-arthritic activity of boswellic acids in bovine serum albumin (BSA)-induced arthritis. Int J Immunopharmacol 1989; 11 (6): 647-52 (Pubitemid 19239439)
87. Wildfeuer A, Neu IS, Safayhi H, et al. Effects of boswellic acids extracted from a herbal medicine on the biosynthesis of leukotrienes and the course of experimental autoimmune encephalomyelitis. Arzneimittelforschung 1998; 48: 668-74 (Pubitemid 28308193)
88. Reichling J, Schmokel H, Fitzi J, et al. Dietary support with Boswellia resin in canine inflammatory joint and spinal disease. Schweiz Arch Tierheilkd 2004;146: 71-9 (Pubitemid 38501810)
89. Duwieja M, Zeitlin IJ, Waterman PG, et al. Anti-inflammatory activity of resins from some species of the plant family Burseraceae. Planta Med 1993; 59: 12-6 (Pubitemid 23055638)
90. Siemoneit U, Hofmann B, Kather N, et al. Identification and functional analysis of cyclooxygenase-1 as a molecular target of boswellic acids. Bio-chem Pharmacol 2008; 75: 503-13 (Pubitemid 350298477)
91. Fleming I. Epoxyeicosatrienoic acids, cell signalling and angiogenesis. Pros-taglandins Other Lipid Mediat 2007; 82: 60-7 (Pubitemid 44880162)
92. Frank A, Unger M. Analysis of frankincense from various Boswellia species with inhibitory activity on human drug metabolizing cytochrome P450 en-zymes using liquid chromatography mass-spectrometry after automated on-line extraction. J Chromatogr A 2006; 1112 (1-2): 255-62
93. Safayhi H, Rall B, Sailer ER, et al. Inhibition by boswellic acids of human leukocyte elastase. J Pharmacol Exp Ther 1997; 281: 460-3 (Pubitemid 27203102)
94. Szekanecz Z, Koch AE. Macrophages and their products in rheumatoid ar-thritis. Curr Opin Rheumatol 2007; 19 (3): 289-95 (Pubitemid 46597469)
95. Mijata J, Tani K, Sato K, et al. Cathepsin G: the significance in rheumatoid arthritis as a monocyte chemoattractant. Rheumatol Int 2007; 27 (4): 375-82 (Pubitemid 46122282)
96. Peters-Golden M, Henderson Jr WR. Leukotrienes. N Engl J Med 2007; 357 (18): 1841-54
97. Ammon HPT. Salai guggal - Boswellia serrata: from a herbal medicine to a non-redox inhibitor of leukotriene biosynthesis. Eur J Med Res 1996; 1: 369-70
98. Fahmi H. mPGES-1 as a novel target for arthritis. Curr Opin Rheumatol 2004; 16 (5): 623-7 (Pubitemid 39128335)
99. 2. Arthritis Res Ther 2005; 7 (3): 114-7 (Pubitemid 40775173)
100. Kojima F, Kato S, Kawai S. Prostaglandin E synthase in the pathophysiology of arthritis. Fundam Clin Pharmacol 2005; 19 (3): 255-61 (Pubitemid 40769448)
101. 2 synthase-1 as a molecular basis for the anti-inflammatory actions of boswellic acids from frankincense. Br J Pharmacol 2011 Jan; 162 (1): 147-62
102. 2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. J Exp Med 1996; 184: 883-91
103. Pungle P, Banavalikar M, Suthar A, et al. Immunomodulatory activity of boswellic acids of Boswellia serrata Roxb. Indian J Exp Biol 2003; 41: 1460-2 (Pubitemid 37506946)
104. Wenzel SE. Arachidonic acid metabolites: mediators of inflammation in asthma. Pharmacother 1997; 17 (1 Pt 2): 3S-12S (Pubitemid 27057108)
105. 2. Trends Immunol 2004; 25 (1): 40-6 (Pubitemid 38032806)
106. Boker DJ, Winking M. Die Rolle von Boswellia serrata in der Therapie maligner Gliome. Deutsches Arzteblatt 1997; 94: B958-60
107. Janssen G, Bude U, Breu H, et al. Boswellic acids in the palliative therapy of children with progressive or relapsed brain tumors. Klin Padiatr 2000; 212: 189-95 (Pubitemid 30650553)
108. Streffer JR, Bitzer M, Schabet M, et al. Response of radiochemotherapy- associated cerebral edema to a phytotherapeutic agent, H15. Neurology 2001; 56 (9): 1219-21 (Pubitemid 32405720)
109. Badie B, Schartner JM, Hagar AR, et al. Microglia cyclooxygenase-2 activity in experimental gliomas: possible role incerebral edema formation. Clin Can Res 2003; 9: 872-7 (Pubitemid 36182627)
110. Ernst E. Frankincense: systematic review. BMJ 2008; 337: a2813
111. Singh S, Khajuria A, Taneja SC, et al. The gastric ulcer protective effect of boswellic acids, a leukotriene inhibitor from Boswellia serrata, in rats. Phytomedicine 2008 Jun; 15 (6-7): 408-15